BIOXCEL THERAPEUTICS INC (BTAI)
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
$0.04-9.04%
Close 2026-10-01 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
Research Workspace
Put BTAI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar under pressure — Improve financial position via capital allocation and debt management: Direct metric needs a verified mapping.
View ThesisRevenue is contracting — down about 15% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 5% on a typical day and fell roughly 99% in its worst 12-month stretch.
View RiskBTAI’s case rests on steady recent financial performance, despite unsteady management. The company was unprofitable over the past year, so earnings quality remains unclear. No earnings release is recorded, so recent growth and the latest result remain unverified. The desk provides no valuation multiple or peer comparison to define what the price reflects. Our model puts the next-quarter miss probability near 86%. A verified mapping is still needed for the pressured capital-allocation and debt-management pillar. No valuation read is available; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-01. BTAI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering BTAI (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare BTAI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BTAI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put BTAI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Address financial challenges
Bankruptcy filing undermines financial stability and growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-01. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Address financial challenges
Earnings miss indicates financial challenges affecting objectives.
